Effectiviteit en verdraagbaarheid van urinezuurverlagende behandeling: Gerandomiseerd gecontroleerd onderzoek van benzbromaron versus probenecide bij jicht na falen van allopurinol

Translated title of the contribution: Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol

M.K. Reinders, E.N. van Roon, T.L.T.A. Jansen, J. Delsing, M.A.F.J. van de Laar, J.R.B.J. Brouwers

    Research output: Contribution to journalArticleAcademicpeer-review

    3 Downloads (Pure)

    Abstract

    Objective: In this study we investigated 1. the efficacy and tolerability of allopurinol (first-choice urate-lowering treatment); 2. the efficacy and tolerability of benzbromarone versus probenecid.
    Design and methods: Randomised controlled, open-label, multi-centre trial of patients recently diagnosed with gout. Patients were given allopurinol 300 mg for two months (stage 1). When allopurinol was not tolerated or failed to attain the target serum urate concentration (sUr) of ≤0.30 mmol/L, patients were randomised to benzbromarone 200 mg/day or probenecid 2000 mg/day and treated for two months (stage 2).
    Results: 96 patients were enrolled in stage 1. 82 patients (85%) were eligible for analysis: using allopurinol, sUr decreased 36% (±11%) from baseline value; 20 patients (24%; 95%CI 16-35) attained target sUr; 9 patients (11%) stopped allopurinol because of adverse drug reactions. 62 patients were enrolled in stage 2: 27 patients received benzbromarone and 35 received probenecid. With benzbromarone 22 out of 24 eligible patients were treated successfully (92%; 95%CI 73-99). Treatment success with probenecid was 20 out of 31 eligible patients (65%; 95%CI 45-81), which was significantly less than with benzbromarone (p = 0.03). Compared with baseline values, sUr decreased 64% (±9%) using benzbromarone and 50% (±7%) using probenecid, which was significantlyless than with benzbromarone (p <0.001).
    Conclusion: In stage 1, we found a poor efficacy and tolerability profile of allopurinol 300 mg/day after two months of treatment. In stage 2, benzbromarone 200 mg/day was more effective and better tolerated than probenecid 2000 mg/day.
    Translated title of the contributionEfficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
    Original languageDutch
    Pages (from-to)19-23
    JournalPharmaceutische Weekblad Wetenschappelijk Platform
    Volume2
    Issue number1
    Publication statusPublished - 2008

    Fingerprint Dive into the research topics of 'Efficacy and tolerability of urate-lowering drugs in gout: A randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol'. Together they form a unique fingerprint.

    Cite this